Michael Franklin, MD
Neurology · Saint Petersburg, FLNPI 1548277189
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.8% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2020 at $7,694 and has fallen 73.1% since, to $2,067 in 2025.
Across 470 payments — averaging $42.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Novartis$687
- Pfizer$566
- GE HealthCare$515
- AstraZeneca$444
- UCB, Inc.$419
- plus $5K from 54 others
What the payments were for
- Speaking & faculty fees$9,82449%
- Travel & lodging$6493%
- Food & beverage$9,51248%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$10,628
How this compares
$20,002 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 75 | $427,668 |
| AubagioTeriflunomide | 30 | $283,597 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $258,154 |
| CopaxoneGlatiramer Acetate | 26 | $150,697 |
| TysabriNatalizumab | 13 | $109,857 |
| TecfideraDimethyl Fumarate | 12 | $105,960 |
| QuliptaAtogepant | 71 | $77,808 |
| Nurtec OdtRimegepant Sulfate | 60 | $59,158 |
| UbrelvyUbrogepant | 54 | $56,783 |
| Teriflunomide | 15 | $51,207 |
| Emgality PenGalcanezumab-Gnlm | 53 | $46,319 |
| Aimovig AutoinjectorErenumab-Aooe | 44 | $40,102 |
| ZavzpretZavegepant Hcl | 27 | $28,804 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $26,242 |
| BotoxOnabotulinumtoxina | 17 | $26,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $24 | $427,66875 claims |
| SanofiAubagio | $179 | $283,59730 claims |
| CSL BehringPrivigen | $93 | $258,15411 claims |
| BiogenTysabri, Tecfidera | $392 | $215,81725 claims |
| AbbVieQulipta, Ubrelvy, Botox | $12,360 | $160,757142 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $270 | $150,69726 claims |
| PfizerNurtec Odt, Zavzpret, Eliquis, Lyrica | $566 | $105,249118 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $26 | $26,24213 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $13 | $14,49320 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $18 | $5,09948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.
Other neurology in Saint Petersburg
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.